Technical Analysis for FENC - Fennec Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade C 4.89 -0.20% -0.01
FENC closed down 0.2 percent on Friday, September 20, 2019, on 59 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical FENC trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Narrow Range Bar Range Contraction -0.20%
Overbought Stochastic Strength 1.88%
Overbought Stochastic Strength -1.01%
1,2,3 Pullback Bullish Bullish Swing Setup -1.21%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.21%
Overbought Stochastic Strength -1.21%
Up 3 Days in a Row Strength -1.21%
Up 4 Days in a Row Strength -1.21%

Older signals for FENC ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
Biopharmaceutical Cancer Disease Oncology Brain Tumor Cancer Therapeutics Neuroblastoma Osteosarcoma Hearing Loss Localized Tumors Neoplasms
Is FENC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.591
52 Week Low 3.255
Average Volume 29,470
200-Day Moving Average 5.1564
50-Day Moving Average 4.4254
20-Day Moving Average 4.596
10-Day Moving Average 4.833
Average True Range 0.2203
ADX 33.44
+DI 23.9792
-DI 10.1054
Chandelier Exit (Long, 3 ATRs ) 4.3491
Chandelier Exit (Short, 3 ATRs ) 4.5709
Upper Bollinger Band 5.175
Lower Bollinger Band 4.017
Percent B (%b) 0.75
BandWidth 25.195822
MACD Line 0.1503
MACD Signal Line 0.1299
MACD Histogram 0.0204
Fundamentals Value
Market Cap 77.09 Million
Num Shares 15.8 Million
EPS -0.29
Price-to-Earnings (P/E) Ratio -16.86
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.01
Resistance 3 (R3) 5.00 4.96 4.99
Resistance 2 (R2) 4.96 4.93 4.97 4.98
Resistance 1 (R1) 4.93 4.92 4.95 4.93 4.97
Pivot Point 4.89 4.89 4.90 4.89 4.89
Support 1 (S1) 4.85 4.86 4.87 4.85 4.81
Support 2 (S2) 4.81 4.84 4.81 4.80
Support 3 (S3) 4.77 4.81 4.79
Support 4 (S4) 4.77